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Abstract
Background: Although the chemopreventive effects of aspirin have been extensively investigated, the roles of
many cell components, such as long non-coding RNAs, in these effects are still not completely understood.
Results: We identify an aspirin-induced upregulated lncRNA, OLA1P2, in human colorectal cancer. Aspirin induces
demethylation of the FOXD3 promoter and promotes expression of the FOXD3 gene. Subsequently, upregulated
FOXD3 protein transcriptionally activates lncRNA OLA1P2 expression. OLA1P2 upregulation markedly affects STAT3
signaling pathway activity by inhibiting the nuclear import of phosphorylated STAT3. The phosphorylation of
tyrosine-705 of STAT3 is the first step in OLA1P2 binding, and the formation of phosphorylated STAT3 homodimers
is subsequently blocked. OLA1P2 interacts directly with STAT3 due to OLA1P2 sharing the same conservative STAT3
transcription response element as STAT3 targets. Regular use of aspirin dramatically decreases the number of
metastatic nodules of cancer cells in immunodeficient mouse lungs, and OLA1P2 silencing markedly weakens
the anti-metastatic activity of aspirin in the lungs. Additionally, low OLA1P2 levels are associated with malignant
transformation and lower overall survival in cancers.
Conclusions: The present study finds that the aspirin-FOXD3-OLA1P2-STAT3 axis exhibits exciting anticancer effects
and provides new insights into the chemopreventive mechanisms underlying aspirin use.
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Background
Multiple randomized controlled trials have demonstrated
that aspirin can protect against different types of cancer,
particularly colorectal cancer (CRC) [1]. Daily use of aspirin
at moderate doses markedly reduces the risk of CRC and is
associated with decreased risk of new CRC in patients with
a personal history of CRC [2, 3]. Even the lowest daily dose
of aspirin was associated with a reduced risk of CRC [4, 5].
The effects of aspirin on inhibiting COX-1-dependent
platelet function represent an important mechanism for
preventing carcinogenesis [6]. Additionally, by inhibiting
PP2A enzymatic activity, aspirin causes the degradation of
phosphorylated β-catenin [7]. Aspirin may act through in-
hibition of the Ras/c-Raf interaction and upregulation of
MKPs to suppress ERK-mediated signaling [8]. Inhib-
ition of NF-kappaB activity by aspirin could make hu-
man colon cancer cells more susceptible to apoptosis [9].
Aspirin also reduces mTOR signaling by inhibiting the
mTOR effectors S6K1 and 4E-BP1 in CRC [10]. Although
the anticancer molecular mechanisms underlying the ef-
fects of aspirin have been extensively investigated, the in-
volvement of a large number of cell components, such as
long non-coding RNAs, is still not completely understood.
Long non-coding RNAs (lncRNAs) have emerged as key
regulators involved in controlling fundamental biological
processes [11]. lncRNA HOTAIR expression is associated
with genome-wide reprogramming of PRC2 function in
CRC, in which upregulation of HOTAIR is a critical element
in metastatic progression [12]. A high expression level of the
lncRNA-CLMAT3 is significantly associated with liver me-
tastasis of CRC and is an independent prognostic indicator
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of survival for patients with CRC [13]. The lncRNA
MYCLos could function in CRC cell proliferation by regulat-
ing MYC target genes, such as p21 [14]. The lncRNA
CCAT1-L, which is transcribed specifically in human CRC,
plays a key role in the transcriptional regulation of MYC
[15]. The lncRNA MALAT1 could promote cell prolifera-
tion and metastasis in CRC by binding to SFPQ and releas-
ing the proto-oncogene PTBP2 from the SFPQ/PTBP2
complex [16]. The lncRNA CCAT2 is highly overexpressed
in CRC, and this lncRNA promotes tumor growth, metasta-
sis, and chromosomal instability through TCF7 L2-mediated
transcriptional regulation [17]. However, little is known
about the regulation and functions of lncRNAs in the treat-
ment of CRC with aspirin.
In this study, we investigated global lncRNA expression
profiles using microarray analysis of CRC cells treated with
aspirin, and we identified the profiles of transcription fac-
tors interacting with the lncRNA OLA1P2 (HGNC: 45277)
promoter via mass spectrometry. We fully analyzed the
mechanisms underlying altered OLA1P2 levels and the ef-
fects on the phenotypes of CRC cells in vitro and in vivo.
Our findings suggested that aspirin could suppress cancer
cell growth and metastasis through the induction of
lncRNA OLA1P2 transcription and the subsequent block-
ing of phosphorylated STAT3 (signal transducer and acti-
vator of transcription 3) homodimers formation.
Results
Aspirin-induced lncRNA OLA1P2 upregulation in
cancer cells
To identify the lncRNA profiles of colorectal carcinoma
(CRC) cells treated with aspirin, we performed microarray
analysis using primary cultured cancer cells obtained from
eight clinical CRC tissues. After the cells were treated with
aspirin, 28 lncRNAs were statistically upregulated more
than two-fold (Fig. 1a). OLA1P2 (HGNC: 45277) was the
most changed lncRNA among these upregulated lncRNAs
(fold change >20) (Fig. 1b). We validated the expression
level of OLA1P2 by qRT-PCR analysis in all eight pairs of
CRC cells with or without aspirin treatment (Fig. 1c).
Using northern blot analysis, we also identified OLA1P1
upregulation in primary cultured CRC cells treated with
aspirin (Fig. 1d). Considering that many digestive system
cancers could possess similar characteristics, we assessed
OLA1P2 expression in other types of cancer cells.
OLA1P2 expression was dramatically induced after aspirin
treatment in oral cancer, gastric cancer, and colon cancer
cell lines, but not in esophageal cancer, liver cancer, and
pancreatic cancer cell lines (Fig. 1e).
Aspirin promoted OLA1P2 transcription through FOXD3
upregulation
To investigate the transcription factors that are respon-
sible for OLA1P2 expression, we performed a pull-down
experiment in the nuclear extract using the biotin-
labeled OLA1P2 promoter. Nuclear proteins of CRC
cells were incubated and pulled down by biotin-labeled
OLA1P2 promoter. One-shot mass spectrometry ana-
lyses were then performed to analyze the purified nu-
clear proteins. As shown in Fig. 2a, 19 proteins were
specifically identified in the aspirin-treated group, and
eight of the proteins (blue-labeled) were previously con-
firmed to be transcription factors or nuclear receptor
coactivators. Using immunoblot analysis, we found that
the SMAD3, FOXD3 (forkhead box D3), NCOA1, and
MEF-2 proteins were dramatically increased in the nu-
cleus following aspirin treatment (Fig. 2b). After these
transcription factors were silenced individually (Fig. 2c),
only FOXD3 dysregulation obviously affected OLA1P2
expression under aspirin treatment (Fig. 2d). Both
FOXD3 mRNA and FOXD3 protein levels in the whole
cell lysate of CRC cells were upregulated under aspirin
treatment (Fig. 2e). In addition, aspirin-induced demeth-
ylation of the FOXD3 promoter may be responsible for
FOXD3 overexpression in CRC cells (Fig. 2e, bottom
lanes). Using chromatin immunoprecipitation analysis,
we showed that part 1 (P1) of the OLA1P2 promoter ex-
hibited a strong binding affinity with the FOXD3 protein
(Fig. 2f, g). We then analyzed the nucleic acid sequence
in greater detail and identified two transcriptional re-
sponse elements for FOXD3 in part 1 of the OLA1P2
promoter (Fig. 2f ). Mutations in the putative FOXD3-
binding sites (the region from -1744 to -1740 bp) ren-
dered the luciferase constructs unresponsive to FOXD3
induction (Fig. 2h) and to aspirin treatment (Fig. 2i).
LncRNA OLA1P2 blocked the nuclear import of
phosphorylated STAT3 (Tyr705)
To identify the targets regulated by OLA1P2, we per-
formed a global gene expression profiling analysis in
OLA1P2-silenced primary cultured cancer cells obtained
from eight clinical CRC tissues. After OLA1P2 was
silenced, 59 genes were statistically upregulated more
than two-fold (Additional file 2: Figure S1). We con-
ducted gene set enrichment analysis (GSEA), which is a
bioinformatics method that determines whether a set of
pathways shows statistically significant enrichment in
the most altered genes [18]. One of the GSEA plots indi-
cated significant enrichment of the STAT3 (signal trans-
ducer and activator of transcription 3) signaling pathway
in the genes regulated by OLA1P2 (P <0.001) (Fig. 3a).
Other related GSEA plots with low enrichment score are
listed in Additional file 2: Figure S1. Using qRT-PCR
analysis, we confirmed these upregulated STAT3 targets
in OLA1P2-silenced cancer cell lines (Additional file 2:
Figure S2). To determine whether STAT3 expression
was regulated by OLA1P2, we infected cancer cells with
a lentivirus expression vector (lenti-OLA1P2) or a short
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hairpin RNA vector (shRNA-OLA1P2) (Fig. 3b; Additional
file 2: Figure S3A). Neither endogenous total STAT3 pro-
tein levels nor phosphorylated STAT3 protein levels were
clearly affected by OLA1P2 (Fig. 3c; Additional file 2:
Figure S3B).
To determine the precise mechanism underlying regula-
tion of STAT3 signaling pathway activity by OLA1P2 in
tumors, we examined the cellular location of OLA1P2.
Using RNA FISH (fluorescent in situ hybridization) tech-
nology, we determined the cytoplasm localization of
OLA1P2 in the COLO205 cells (Fig. 3d). By isolating both
nuclear and cytoplasmic RNA, we confirmed that
OLA1P2 was mainly present in the cytoplasm (Fig. 3e).
To determine whether phosphorylated STAT3 protein
translocation was regulated by OLA1P2, we separated this
protein from the cytoplasm and nuclear extracts. The
nuclear import of phosphorylated STAT3 (Tyr705) pro-
tein, but not phosphorylated STAT3 (Ser727) protein, was
largely blocked when OLA1P2 was overexpressed (Fig. 3f;
Additional file 2: Figure S3C). In contrast, the nuclear im-
port of phosphorylated STAT3 (Tyr705) protein, but not
phosphorylated STAT3 (Ser727) protein, was dramatically
Fig. 1 Aspirin-induced lncRNA OLA1P2 upregulation in cancer cells. a Primary cultured colon cancer cells were treated with aspirin (100 μM) for
48 h and then evaluated to determine their lncRNA profiles using an lncRNA expression microarray. Red indicates high expression; blue indicates
low expression. b A volcano plot showing the relationship between the P values and the magnitude of the differences in the expression values
of the samples in the different groups. c The expression level of OLA1P2 was validated by qRT-PCR analysis in all eight pairs of CRC cells with or
without aspirin treatment. d Primary cultured colon cancer cells were treated with aspirin (100 μM) for 48 h and then evaluated for OLA1P2
expression using northern blotting analysis. e Cancer cell lines were treated with aspirin (100 μM) for 48 h and then evaluated for OLA1P2 expression
using qRT-PCR analysis
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Fig. 2 Aspirin promoted OLA1P2 transcription through FOXD3 upregulation. a The biotin-labeled OLA1P2 promoter was mixed with the nuclear
extract separated from DMSO/aspirin-treated primary culture cancer cells. The eluted proteins were then analyzed using mass spectrometry
methods. b The protein levels in the nuclei of primary cultured cells treated with aspirin (100 μM) for 48 h were analyzed using immunoblotting
methods. c Protein levels in primary culture cancer cells transfected with shRNA vectors for 48 h were analyzed by immunoblot. d OLA1P2 expression
was analyzed by qRT-PCR methods in primary culture cancer cells transfected with the shRNA vector for 48 h and then treated with aspirin (100 μM)
for 48 h. e QRT-PCR analysis of FOXD3 mRNA expression in CRC cells treated with aspirin (top lanes). Immunoblot analysis of FOXD3 protein levels in
CRC cells treated with aspirin (middle lanes). Quantitative methylation-specific PCR analysis of FOXD3 promoter methylation levels in CRC cells treated
with aspirin (bottom lanes). M: methylation-specific primer; U: unmethylation-specific primer. f Diagram showing conserved FOXD3 response elements
in the OLA1P2 promoter. g ChIP assays using anti-FOXD3 or anti-IgG antibodies were performed to determine the affinity of FOXD3 for the OLA1P2
promoter in primary culture cancer cells. h Primary culture cancer cells were co-transfected with the lenti-FOXD3 vector and a luciferase reporter for
48 h. i Primary culture cancer cells were transfected with a luciferase reporter for 12 h and were then treated with aspirin (100 μM) for 48 h. **: P <0.01;
***: P <0.001
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promoted when OLA1P2 was silenced (Fig. 3g; Additional
file 2: Figure S3D).
LncRNA OLA1P2 directly interacted with phosphorylated
STAT3 (Tyr705)
RNA immunoprecipitation (RIP) experiments demon-
strated that endogenous OLA1P2 was markedly recov-
ered by the phosphorylated STAT3 (Tyr705) protein
(Fig. 4a; Additional file 2: Figure S4A). We performed an
RNA pull-down assay using 5′ biotin-linked RNAs, and
the results indicated that the phosphorylated STAT3
(Tyr705) protein, but not the phosphorylated STAT3
(Ser727) protein, could be pulled down in the OLA1P2-
treated group (Fig. 4b; Additional file 2: Figure S4B).
Furthermore, a point mutation at the phosphorylated
site (Y705R) of the STAT3 protein abrogated the affinity
of STAT3 and OLA1P2 (Fig. 4c). RNA FISH technology
combined with immunofluorescence analysis confirmed
the co-localization of lncRNA OLA1P2 and phos-
phorylated STAT3 (Tyr705) protein in the cancer cells
(Fig. 4d).
To investigate the region of OLA1P2 responsible for
the binding activity with phosphorylated STAT3, we
designed various primers to detect different fragments of
OLA1P2. Only part 1 (P1) of OLA1P2 was markedly
recovered by the phosphorylated STAT3 (Tyr705)
protein (Fig. 4e; Additional file 2: Figure S4C). The
phosphorylated STAT3 (Tyr705) protein, but not the
Fig. 3 OLA1P2 affected the translocation of the phosphorylated STAT3 protein. a GSEA demonstrated enrichment of STAT3 target genes. The
top of the panel shows the enrichment scores for genes associated with STAT3 signaling pathway targets. The black lines represent the 17 most
highly correlated targets. The bottom of the panel shows the ranking scores (correlations of all genes associated with STAT3 signaling pathway
targets with aspirin). b QRT-PCR analysis of OLA1P2 expression in the colon cancer cell line COLO205 transfected with lenti-OLA1P2,
shRNA-OLA1P2, or negative controls. c Total STAT3 protein and phosphorylated STAT3 protein levels were analyzed by immunoblot in COLO205
cells transfected with lenti-OLA1P2 or shRNA-OLA1P2. d RNA FISH analysis of OLA1P2 localization in COLO205 cells. e QRT-PCR analysis of OLA1P2
localization. OLA1P2 was mainly present in the cytoplasm. U2 RNA was used as a positive control for nuclear RNA. f Phosphorylated
STAT3 protein levels in the cytoplasm and nuclei of COLO205 cells transfected with lenti-OLA1P2 were analyzed by immunoblot analysis.
g Phosphorylated STAT3 protein levels in the cytoplasm and nuclei of COLO205 cells transfected with shRNA-OLA1P2 were analyzed by
immunoblot analysis. ***: P <0.001
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phosphorylated STAT3 (Ser727) protein, could be
pulled down by OLA1P2-P1 (Fig. 4f; Additional file 2:
Figure S4D). In further analyses, we identified an evo-
lutionarily conserved STAT3 transcriptional response
element in part 1 of OLA1P2 (Fig. 4g). When this
STAT3 transcriptional response element was mutated,
the phosphorylated STAT3 (Tyr705) protein could not
be effectively pulled down in the OLA1P2-mutated-
treated group (Fig. 4h; Additional file 2: Figure S4E).
LncRNA OLA1P2 blocked the formation of
phosphorylated STAT3 homodimers
Overexpression of OLA1P2 markedly blocked the for-
mation of phosphorylated STAT3 homodimers, whereas
silencing of OLA1P2 promoted the formation of
phosphorylated STAT3 homodimers (Fig. 5a). The results
of polyacrylamide gel electrophoresis under non-
denaturing conditions indicated that OLA1P2 could only
bind with phosphorylated STAT3 (Tyr705) monomers
and did not interact with phosphorylated STAT3 (Tyr705)
homodimers (Fig. 5b). We next determined whether
OLA1P2 was capable of blocking the formation of phos-
phorylated STAT3 homodimers by conducting a competi-
tion assay. After STAT3 was phosphorylated by purified
JAK2 enzymatic reactions, the variant amount of purified
OLA1P2 produced by in vitro RNA synthesis was added
to the reaction mixture (Fig. 5c). We found that OLA1P2
significantly blocked the formation of phosphorylated
STAT3 (Tyr705) homodimers in the presence of 200 pmol
purified OLA1P2 (Fig. 5d). Next, we modified the
Fig. 4 OLA1P2 interacted directly with phosphorylated STAT3 (Tyr705). a RIP analysis determined the recovery of OLA1P2 in COLO205 cells using
STAT3 or phosphorylated STAT3 antibodies. b RNA pull-down analysis determined the phosphorylated STAT3 protein-lncRNA OLA1P2 interaction in
COLO205 cells using 5′ biotin-linked RNAs. c After cells were transfected with the STAT3 expression vector (wt/Y705R) for 48 h, RNA pull-down analysis
determined the STAT3 protein-OLA1P2 interaction in COLO205 cells using 5′ biotin-linked RNAs. d RNA FISH technology and immunofluorescence
analysis determined the co-localization of OLA1P2 and phosphorylated STAT3 (Tyr705) protein in COLO205 cells. e RIP analysis to determine the
recovery of a portion of OLA1P2 in COLO205 cells transfected with lenti-OLA1P2 using phosphorylated STAT3 (Tyr705) antibody. f RNA pull-down
analysis to determine the interaction of phosphorylated STAT3 protein with a portion of OLA1P2 using 5′ biotin-linked RNAs. g Diagram showing the
conserved STAT3 transcriptional response element in part 1 of OLA1P2. h RNA pull-down analysis to determine the interaction of phosphorylated
STAT3 with mutated OLA1P2 in COLO205 cells. ***: P <0.001
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experimental design to determine whether the endogen-
ous OLA1P2 in COLO205 cells could block the formation
of phosphorylated STAT3 (Tyr705) homodimers in vitro.
QRT-PCR was used to determine the amount of endogen-
ous OLA1P2 in COLO205 cells treated with aspirin and
shRNA-OLA1P2 (Fig. 5e). Total RNA extracted from
COLO205 cells was used instead of purified OLA1P2
(Fig. 5f). Following in vitro incubation and purification,
we demonstrated that 50 μg total cellular RNA containing
endogenous OLA1P2 successfully blocked the formation
of phosphorylated STAT3 (Tyr705) homodimers (Fig. 5g).
OLA1P2 mediated the aspirin-induced anti-metastatic
phenotype and was associated with malignant
transformation in CRC
To investigate whether the transcriptional activity of the
phosphorylated STAT3 (Tyr705) protein was affected by
OLA1P2, we performed luciferase reporter analysis using
Fig. 5 OLA1P2 blocked the formation of phosphorylated STAT3 homodimers. a A total of 293 T cells were transfected with indicated plasmids for
48 h and then treated with IL-6 for 24 h. Immunoprecipitation and immunoblotting analysis were performed to analyze STAT3-Flag and STAT3-HA
protein levels. b COLO205 cells were subjected to RNA pull-down analysis using 5′ biotin-linked RNAs, and the eluted proteins were
determined using immunoblotting analysis following polyacrylamide gel electrophoresis under non-denaturing conditions. c Schematic
diagram showing the experimental design of purified OLA1P2 blocking the formation of phosphorylated STAT3 homodimers. We used 4 μg purified
STAT3 (2 μg STAT3-Flag combined with 2 μg STAT3-HA) incubated with 2 μg purified JAK2. After incubation, purified OLA1P2 was then added to the
reaction mixture. d Different amount of purified OLA1P2 blocking the formation of phosphorylated STAT3 homodimers. e QRT-PCR analysis of the
amount of lncRNA OLA1P2 in COLO205 cells treated with aspirin and shRNA-OLA1P2. f Schematic diagram showing the modified experimental design
of total RNA containing OLA1P2 blocking the formation of phosphorylated STAT3 homodimers. We used 4 μg purified STAT3 (2 μg STAT3-Flag combined
with 2 μg STAT3-HA) incubated with 2 μg purified JAK2. After incubation, total RNA extracted from COLO205 cells were then added to the reaction
mixture. g The total RNA of OLA1P2 silencing COLO205 cells failed to block the formation of phosphorylated STAT3 homodimers
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a STAT3 reporter. Overexpression of OLA1P2 markedly
suppressed luciferase activity, whereas silencing of
OLA1P2 increased luciferase activity (Additional file 2:
Figure S5A-D). Almost all of the STAT3 targets partici-
pated in cell growth were dramatically regulated by
OLA1P2 (Additional file 2: Figure S5E-G). We further
observed the anti-proliferative activity of OLA1P2 in
cancer cell lines (Additional file 2: Figure S6A-C);
OLA1P2 largely mediated the anti-invasive activity of
aspirin in different cancer cell lines (Additional file 2:
Figure S6D).
The effects of OLA1P2 on metastasis were also evalu-
ated in vivo. Immunodeficient mice were pretreated with
aspirin via oral administration for 8 weeks, after which
cancer cells infected with either shRNA-OLA1P2 or a
negative control were injected into the tail veins of
immunodeficient mice. After 72 h, we observed that
OLA1P2 silencing markedly weakened the anti-metastatic
activity of aspirin in the lungs (Fig. 6a; Additional file 2:
Figure S7A). After 4 weeks, histological analyses con-
firmed that the number of metastatic nodules was mark-
edly reduced in the lungs of mice treated with aspirin
alone, and OLA1P2 silencing significantly weakened the
anti-metastatic activity of aspirin (Fig. 6b; Additional
file 2: Figure S7B).
Increased levels of OLA1P2 in clinical cancer tissues ob-
tained from patients with regular use of aspirin were de-
termined by qRT-PCR analysis (Fig. 6c; Additional file 2:
Figure S8A). Upregulated FOXD3 protein levels and
downregulated phosphorylated STAT3 (Tyr705) protein
levels were identified by immunoblot analysis in nuclear
extracts of clinical cancer samples obtained from patients
who regularly used aspirin (Fig. 6d; Additional file 2:
Figure S8B). We found a significant inverse correlation be-
tween FOXD3 protein levels and phosphorylated STAT3
(Tyr705) protein levels in nuclear extracts of clinical
cancer samples obtained from patients who regularly
used aspirin (Fig. 6e; Additional file 2: Figure S8C).
Lower levels of OLA1P2 correlated with more ad-
vanced pathology grade, suggesting an association be-
tween OLA1P2 expression and tumor progression
(Fig. 6f; Additional file 2: Figure S9A, B). Further-
more, OLA1P2 levels below the mean correlated with
lower overall survival of patients with CRC (Fig. 6g;
Additional file 2: Figure S9C, D). In addition, we de-
termined the expression of FOXD3 protein and phos-
phorylated STAT3 (Tyr705) protein in clinical samples
using immunohistochemical analysis (Additional file 2:
Figure S9E, G). Negligible and weak FOXD3 expression
correlated with lower overall survival of patients with
CRC (Additional file 2: Figure S9F). Moderate and strong
phosphorylated STAT3 (Tyr705) expression correlated
with lower overall survival of patients with CRC
(Additional file 2: Figure S9H).
In conclusion, regular use of aspirin induced demeth-
ylation of the FOXD3 promoter and promoted expres-
sion of the FOXD3 gene. Upregulated FOXD3 protein
transcriptionally activated lncRNA OLA1P2 expression.
Then, OLA1P2 overexpression resulted in direct binding
of OLA1P2 with phosphorylated STAT3 (Tyr705) and
blocked the formation of phosphorylated STAT3 homo-
dimers (Fig. 6h).
Discussion
A large body of evidence has indicated that lncRNAs are
involved in chemopreventive effects [19, 20]. In this
study, we investigated lncRNA expression profiles in re-
sponse to aspirin treatment in CRC cells and identified
an aspirin-induced upregulated lncRNA, OLA1P2. Im-
portantly, lower levels of OLA1P2 correlated with more
advanced pathology grade and lower overall survival of
patients with CRC. Within the first 2 years after surgery
for patients with CRC, the majority of residual cancer
cells often undergo a period of dormancy, a stage in can-
cer progression in which residual disease is present but
remains asymptomatic [21]. Regardless of high or low
OLA1P2 expression, the survival curve did not differ
within the first 2 years due to the lower probability of
cancer recurrence for all patients with CRC. More than
2 years after surgery, OLA1P2 overexpression may
suppress cancer cell proliferation and metastasis, thus
resulting in a lower rate of cancer recurrence. In
addition to CRC, OLA1P2 was also markedly induced by
aspirin in oral cancers and gastric cancers. These results
indicated that aspirin might share the same chemo-
therapy mechanism involving OLA1P2 induction in oral
cancer, gastric cancer, and CRC. However, OLA1P2 was
not found to serve as a key mediator of aspirin treat-
ment in esophageal cancer, liver cancer, or pancreatic
cancer, although clinical trials have indicated that aspirin
significantly reduces the risks of these cancers [22–24].
Our research indicated that different anticancer mecha-
nisms likely underlie the chemoprotective effects of
aspirin use on digestive system cancers.
We found that aspirin induced OLA1P2 expression
through FOXD3 upregulation. FOXD3 belongs to the
forkhead family of transcription factors. Its role in
tumorigenesis has recently attracted attention [25]. Fur-
thermore, the FOXD3 tumor-suppressive cascade was
downregulated in human cancers mainly due to DNA
methylation [26]. Our results confirmed that demethyla-
tion of the FOXD3 promoter induced by aspirin might
be responsible for the overexpression of FOXD3 in CRC
cells. Aspirin dramatically increased FOXD3 concentra-
tions in the nuclei of cancer cells and effectively pro-
moted FOXD3 interaction with OLA1P2 promoter
regions, providing convincing evidence that FOXD3 is a
new aspirin target that could function in the control of
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Fig. 6 (See legend on next page.)
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lncRNA transcription. In addition, given that FOXD3 is
critical for the maintenance of self-renewal, survival, and
pluripotency in human embryonic stem cells [27], inves-
tigating the roles of aspirin in embryonic organ develop-
ment may be valuable.
Many new functions have been assigned to non-
coding RNAs in the cytoplasm. A muscle-specific
lncRNA, linc-MD1, displays decoy activity for two spe-
cific miRNAs (miR-133 and miR-135) and regulates the
expression of MAML1 and MEF2C in a molecular
circuitry affecting the differentiation program [28]. All
MRE (microRNA response element)-containing tran-
scripts in the cytoplasm, including lncRNA, transcribed
pseudogenes, and even protein-coding RNA, are capable
of regulating each other through ceRNA (competing
endogenous RNAs) activity [29]. Our results confirmed
that aspirin-induced OLA1P2 was mainly enriched in
the cytoplasm. Cytoplasmic OLA1P2 affected the STAT3
signaling pathway activity by inhibiting the nuclear
import of phosphorylated STAT3. The accumulation of
STAT3 in the nucleus was tightly controlled. A number
of factors regulate the phosphorylation status of STAT3
and alter its nuclear import-export dynamics [30].
Cao et al. determined that the lncRNA lnc-DC could
bind directly to STAT3 in the cytoplasm, promoting
STAT3 phosphorylation at tyrosine-705 by preventing
STAT3 from binding to and being dephosphorylated by
SHP1 [31]. We found that the phosphorylation of
tyrosine-705 of STAT3 was the first step in OLA1P2 bind-
ing and that the formation of phosphorylated STAT3
homodimers was subsequently blocked by OLA1P2.
OLA1P2 directly interacted with STAT3 due to OLA1P2
sharing the same conservative STAT3 transcription re-
sponse element as STAT3-activated targets. Given that in-
hibition of STAT3 homodimers formation diminished
STAT3 activity, STAT3 may represent a potential thera-
peutic target for OLA1P2 in cancer chemotherapy.
Our results established a new link between FOXD3,
STAT3, and OLA1P2. FOXD3 is an important tumor
suppressor that suppresses the growth, invasion, and
metastasis of cancer cells [32]. Aberrant activation of
STAT3 has been reported in many types of tumors;
STAT3 plays an oncoprotein role in tumorigenesis [33].
Maintaining cellular homeostasis by balancing these
counter-signaling pathways is important for cell survival.
Our results showed that overexpression of FOXD3
induced by aspirin could indirectly suppress STAT3
signaling pathway activity, which is mediated by the
lncRNA OLA1P2. Here, lncRNAs represent a new layer
of regulatory circuitry in which different types of cell
components (both proteins and non-coding RNAs) can
exhibit cross-talk and determine cell fates.
In this study, we investigated the lncRNA expression
profiles associated with aspirin treatment and showed
that lncRNA OLA1P2 could be dramatically induced by
aspirin in cancer cells. Regular use of aspirin induced
demethylation of the FOXD3 promoter and promoted
expression of the FOXD3 gene. Upregulated FOXD3
protein transcriptionally activated lncRNA OLA1P2 ex-
pression. Then, OLA1P2 overexpression resulted in
direct binding of OLA1P2 with phosphorylated STAT3
(Tyr705) and blocked the formation of phosphorylated
STAT3 homodimers. The aspirin-FOXD3-OLA1P2-STAT3
axis showed exciting antitumor effects in relation to
cancer treatment. Our research provides new insight
into the chemopreventive mechanisms associated with
aspirin use.
Conclusions
We identified an aspirin-induced upregulated lncRNA,
OLA1P2, in human CRC, oral cancer, and gastric cancer
cells. OLA1P2 upregulation markedly affected STAT3
signaling pathway activity by inhibiting the formation of
phosphorylated STAT3 homodimers. The findings of this
study show that the aspirin-FOXD3-OLA1P2-STAT3
axis exhibits exciting anticancer effects and provide new
insight into the chemopreventive mechanisms under-
lying aspirin use.
(See figure on previous page.)
Fig. 6 OLA1P2 mediated the aspirin-induced anti-metastatic phenotype and were associated with lower overall survival in CRC. a Stable
OLA1P2-silencing COLO205 cells were injected into the immunodeficient mice, which were evaluated to determine the lung colonization capacity in
tail vein assays. The bar graph represents 72 h time point measurements of the normalized photon flux for the animals. Representative images are
shown; n = 6 for each group. b Number of metastases in the lungs of mice 4 weeks after tail vein injection; mean nodules per lung values are shown
(bottom). Representative H&E staining of metastatic lung tumor tissues are shown (top). c Increased levels of OLA1P2 in clinical CRC tissues obtained
from patients with regular use of aspirin were determined by qRT-PCR. d Immunoblotting analysis determined the protein levels of FOXD3 and
phosphorylated STAT3 (Tyr705) in nuclear extract of clinical CRC samples obtained from patients with or without regular use of aspirin. e Linear
regression analysis revealed the inverse correlation between FOXD3 and phosphorylated STAT3 (Tyr705) protein levels in nuclear extract of CRC tissues
obtained from patients with regular use of aspirin (n = 46). f Lower OLA1P2 levels were correlated with increased pathological grade of CRC. g The
curves show the lower overall survival of CRC patients with low OLA1P2 levels compared with CRC patients with high OLA1P2 levels. h A model
illustrating the putative roles of aspirin-induced OLA1P2 in controlling the formation of phosphorylated STAT3 homodimers. *: P <0.05; **: P <0.01;
***: P <0.001
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Methods
Patients
Between April 2007 and April 2009, we recruited 292
patients with primary GC from Shanghai Cancer Center,
Fudan University. All patients (excluding stages IV dis-
ease) underwent R0 resection with D2 lymph node dis-
section and all patients histopathologically confirmed
diagnosis of stages II and III gained chemotherapy-based
fluorouracil of six to eight courses following operation.
Between July 2007 and May 2010, we recruited 170 pa-
tients with oral cancer from Ninth People’s Hospital,
Shanghai Jiao Tong University School of Medicine.
Early-stage disease (stages I and II) was primarily
managed with radical neck dissection. Advanced-stage
disease (stages III and IV) underwent radical neck
dissection with postoperative radiotherapy. Between
September 2008 and December 2010, we recruited 196
patients with primary CRC from Ruijin Hospital, Shanghai
Jiao Tong University School of Medicine. Patients under-
went surgery for CRC with histological grade Dukes A, B,
or C. Patients also received postsurgical adjuvant chemo-
therapy (Dukes C). A preoperative history of daily use of
aspirin (>70 mg per day) for more than 3 years were
defined as regular use of aspirin.
Cell lines
All human cancer cell lines (SCC-9, SCC-15, SCC-25,
TE-1, TE-2, TE-8, AGS, SNU-1, NCI-N87, COLO205,
LoVo, SW620, HepG2, Hep3B, SMMC7721, PANC-1,
SW1990, and Capan-1) were obtained from the American
Type Culture Collection (Manassas, VA, USA).
LncRNA microarray analysis
LncRNA expression profiles were investigated using the
Agilent Human lncRNA array 8*60 K (OE Biotech,
Shanghai, China) (GEO: GSE76583). The RNA samples
were first reverse transcribed into cDNA, and these
cDNA samples were then labeled using a Low Input
Quick-Amp Labeling Kit (Agilent Technologies, Santa
Clara, CA, USA). Labeled cDNA samples were used as
probes to hybridize to lncRNA microarrays. After the
samples were hybridized, the microarrays were scanned
with an Agilent microarray scanner. Feature Extraction
software (version 10.7.1.1, Agilent Technologies) was
used to analyze array images to obtain raw data. Gene-
Spring software (version 12.5, Agilent Technologies)
was employed to finish the basic analysis of the raw
data. Initially, the raw data were normalized using the
quantile algorithm. The probes with at least 100% of
samples in any one condition out of two conditions
having flags that indicate ‘Detected’ were chosen for
further data analysis. Differentially expressed lncRNAs
were then identified through fold change, and P values
were calculated using t-tests. The thresholds set for up-
and downregulated genes were a fold change ≥2.0 and a
P value ≤0.05.
Northern blot analysis
OLA1P2 levels were measured by northern blot using an
Ambion Northern Max-Gly Kit (Austin, TX, USA). Total
RNA was electrophoresed and siphoned to a positively
charged nylon membrane (NC). RNA was then fixed to
the NC membrane using UV cross-linking. Briefly, the
cross-linked membrane was then prehybridized with
ULTRAhyb, and RNA was detected with an OLA1P2-
specific oligonucleotide probe (5′-TCAGCACTCAA
TTCTTGCCAA-3′) labeled with digoxigenin-ddUTP
using a DIG Oligonucleotide 3′-End Labeling Kit (Roche
Diagnostics, Indianapolis, IN, USA) in roller bottles.
Biotin-promoter pull-down assay and mass spectrometry
Double-stranded OLA1P1 promoter was synthesized by
PCR and labeled with biotin-14-dCTP according to the
manufacturer’s instructions (19518-018, Invitrogen,
Grand Island, NY, USA). Biotin-labeled DNA was di-
luted in 10 mM Tris-HCl, 10 mM MgCl2, 25 mM NaCl,
and 10 % glycerol and incubated with nuclear protein
extract at 4 °C for 12 h. In total, 100 μL streptavidin-linked
magnetic beads (88816, Thermo Scientific, Waltham, MA
USA) was used to pull down the biotinylated DNA at room
temperature for 2 h. The beads-DNA-proteins were then
washed with 1× binding and washing buffer (5 mM Tris-
HCl, 1 M NaCl, 0.5 mM EDTA, and 0.005 % Tween 20)
four times. The proteins were precipitated and diluted in
100 μL protein lysis buffer. One-shot mass spectrometry
analyses were then performed to analyze the purified
nuclear proteins.
ChIP analysis
Five hundred million cells were fixed in 1 % formalde-
hyde for 30 min at room temperature, and then DNA
was sheared to an average fragment size of 500 to 1,000
bp by sonication. Subsequently, chromatin was immu-
noprecipitated with biotin-labeled FOXD3 antibody. A
positive control antibody (RNA polymerase II/RPII), a
negative control normal mouse IgG, and GAPDH
primers were used as controls to demonstrate the effi-
cacy of the kit reagents (P-2025-48, Epigentek Group,
Brooklyn, NY, USA). Purified chromatin was quantified
by qRT-PCR using PowerUp™ SYBR® Green Master Mix
(Life Technologies, Grand Island, NY, USA). The primer
pairs used for this analysis are described in Additional
file 1: Table S1. Signals obtained from the ChIP assay
were divided by signals obtained from an input sample.
This input sample represented the amount of chromatin
used in the ChIP assay. Here, 1 % of starting chromatin
was used as the input, and then a dilution factor of 100
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or 6.644 cycles (log2 of 100) was subtracted from the Ct
value of diluted input.
Plasmid construction
The full-length sequences of OLA1P2 and the STAT3
gene were amplified using PCR methods (the primer
pairs used for this analysis are described in Additional
file 1: Table S1). The PCR products were first sub-cloned
into the T vector and subsequently cloned into the lenti-
viral plasmid FUGW (Addgene, Cambridge, MA, USA).
We used a Phusion Site-Directed Mutagenesis Kit (Life
Technologies, Grand Island, NY, USA) for construction of
the mutated STAT3 vector (STAT3Y705R-HA). The
pLKO.1 (Addgene, Cambridge, MA, USA) lentiviral sys-
tem was used for stable knock down of OLA1P2. The
shRNA construct was made by cloning the double-
stranded oligos shOLA1P2 (forward oligo: 5′-CCGG
aaGUGCUUUGCCAAAGAUCAUua CTCGAG taATGA
TCTTTGGCAAAGCACtt TTTTTG-3′; reverse oligo:
5′-AATTCAAAAA aaGUGCUUUGCCAAAGAUCAUua
CTCGAG taATGATCTTTGGCAAAGCACtt-3′) in AgeI
and EcoRI sites of pLKO.1.
Lentivirus package
The 293 T cells were cultured in Dulbecco’s modified
Eagle’s medium (Gibco, Grand Island, NY USA)
supplemented with 10 % (vol/vol) fetal bovine serum
and transfected with 3 μg pLKO-shOLA1P2/pLenti-
OLA1P2, 1 μg pCMV-VSV-G, and 3 μg pCMV-Delta8.9
using Lipofectamine 2000 reagent (Invitrogen, Grand
Island, NY USA). After the cells were incubated over-
night, the medium was replaced with 10 mL fresh
medium. The virus-containing supernatants were col-
lected at 48 and 72 h after transfection and then filtered
using a 0.45 μm cellulose acetate filter (Sartorius,
Bohemia, NY, USA).
RNA extraction and qRT-PCR analysis
Total RNA was extracted from cancer cells using
TRIzol Reagent (Invitrogen, Shanghai, China), and
cDNA was synthesized using a PrimeScript RT re-
agent kit (Takara, Kusatsu, Shiga, Japan). A PCR ana-
lysis was performed using PowerUp™ SYBR® Green
Master Mix (Life Technologies, Grand Island, NY,
USA), and amplified PCR products were quantified
and normalized using GAPDH as a control. The PCR
cycle parameters for OLA1P2 and FOXD3 expression
were as follows: 1 cycle of 95 °C for 5 min followed
by 40 cycles of 94 °C for 10 s and 65 °C for 40 s,
with a final extension at 72 °C for 10 min. The primer
pairs used for this analysis are described in Additional
file 1: Table S1.
Western blot analysis
Cells were harvested at the indicated times and rinsed
twice with PBS. Cell extracts were prepared with lysis
buffer and centrifuged at 13,000 g for 10 min at 4 °C.
Protein samples (100 μg) were electrophoresed using 10
% polyacrylamide gels and transferred to PVDF mem-
branes. After the membranes were blocked with 5 %
BSA for 1 h at room temperature, they were incubated
with FOXD3 antibody (ab67758, 1:1,000, Abcam,
Cambridge, MA, USA), STAT3 antibody (#4904, 1:2,000,
Cell Signaling, Danvers, MA, USA), p-STAT3(Tyr705)
antibody (sc-8059, 1:1,000, Santa Cruz, Dallas, TX,
USA), p-STAT3(Ser727) antibody (sc-293059, 1:1,000,
Santa Cruz, Dallas, TX, USA), Flag antibody (ab49969,
1:3,000, Abcam, Cambridge, MA, USA) or HA antibody
(ab18230, 1:3,000, Abcam, Cambridge, MA, USA) in 5 %
BSA overnight at 4 °C. Secondary antibodies (1:3,000)
were labeled with horseradish peroxidase (HRP). The
signals were checked by autoradiography film when HRP
substrate was added to the membranes.
RNA FISH and protein immunofluorescence analysis
Cancer cells cultured on a glass coverslip were fixed in 4
% paraformaldehyde for 30 min and permeabilized with
0.1 % Triton X-100 for 30 min. The cells were washed
three times with PBS and treated with pre-hybridization
buffer (2× saline-sodium citrate) containing 10 % form-
amide. Hybridization was performed using a similar buf-
fer, but with the addition of competitor RNA (tRNA)
and competitor protein (BSA) to reduce background.
The FITC-labeled OLA1P2 probe (5′-TCAGCACT
CAATTCTTGCCAA-3′), which was diluted in hybri-
dization buffer (200 μL), was deposited on a surface in a
humid dark chamber. The glass coverslip was then
placed face down on the drop and incubated at 37 °C for
12 h. After the cells were incubated with the OLA1P2
probe, the cells were washed five times with PBS and
treated with p-STAT3 (Tyr705) antibody (sc-8059, 1:50,
Santa Cruz, Dallas, TX, USA) for 2 h at 37 °C. The cells
were washed five times with PBS and treated with anti-
mouse fluorescent-labeled secondary antibody for 1 h at
37 °C. We continued with several rounds of washing
(which also included an optional DAPI staining step)
and finishing with mounting the coverslip onto a micro-
scope slide using an anti-fade mounting medium.
Cytoplasmic and nuclear RNA isolation
Cytoplasmic and nuclear RNA was extracted using
Thermo Fisher BioReagents (Thermo Fisher, Grand
Island, NY, USA) according to the manufacturer’s
instructions. QRT-PCR analysis was performed using
PowerUp™ SYBR® Green Master Mix (Life Technologies,
Grand Island, NY, USA) to amplify the localization of
OLA1P2 assay. The qRT-PCR conditions were as
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follows: 1 cycle of 95 °C for 5 min followed by 40 cycles
of 94 °C for 10 s and 65 °C for 40 s, with a final exten-
sion at 72 °C for 10 min. The primer pairs used for this
analysis are described in Additional file 1: Table S1.
RNA immunoprecipitation analysis
Cancer cells were harvested by trypsinization and mech-
anically sheared using a homogenizer. Biotin-labeled
STAT3 and phosphorylated STAT3 antibodies were
added to the cell extract and incubated overnight at
4 °C. Streptavidin-coated magnetic beads were then
added and incubated for 4 h at 4 °C. Magnetic beads were
pelleted, washed, and re-suspended in 1 mL TRIzol. The
isolated RNA was reverse transcribed to cDNA and then
analyzed by qRT-PCR. The PCR cycle parameters for
OLA1P2 enrichment were as follows: 1 cycle of 95 °C for
5 min followed by 40 cycles of 94 °C for 10 s and 65 °C for
40 s, with a final extension at 72 °C for 10 min. The pri-
mer pairs used for this analysis are described in Additional
file 1: Table S1.
RNA pull-down analysis
The biotinylated OLA1P2, antisense OLA1P2, or mu-
tated OLA1P2 was mixed with proteins obtained from
cancer cells for overnight at 4 °C. The complex of bio-
tinylated lncRNA and proteins was purified using
streptavidin-agarose for 4 h at 4 °C. The proteins are
then eluted from the RNA-protein complex and detected
by western blotting analysis.
LncRNA-protein binding assay in vivo
The purified JAK2 protein from 293 T cells was washed
three times with kinase assay buffer (10 mM HEPES
[pH 7.4], 50 mM NaCl, 5 mM MgCl2, 5 mM MnCl2,
50 mM NaF, and 0.003 mM Na3VO4). The JAK2 pro-
tein (2 μg) was then incubated with the purified
STAT3 protein (4 μg) and 250 μM adenosine triphos-
phate (ATP). Purified STAT3 protein was used as a
substrate for each assay. The reaction system was in-
cubated for 120 min at room temperature. After incu-
bation, serial dilutions of purified lncRNA OLA1P2 or
total RNA extracted from COLO205 cells were then
added to the reaction mixture at room temperature
for 120 min. Each reaction was then divided into
three parts: the first part was used as an input, the
second part was used for immunoprecipitation assay
with Flag beads, and the third part was used for im-
munoprecipitation assay with HA beads. Eluted pro-
teins were then subjected to polyacrylamide gel
electrophoresis under non-denaturing conditions.
In vivo analysis
Immunodeficient mice were pretreated with aspirin via
oral administration (40 mg/kg) for 8 weeks, after which
cancer cells (1 × 106) stably silencing OLA1P2 were
injected into the tail veins of immunodeficient mice
(n = 6). Xenografts were then treated with aspirin at a
dose of 40 mg/kg, administered daily via oral gavage.
After 72 h, the lung colonization capacity of the can-
cer cells was analyzed based on the normalized pho-
ton flux.
Hematoxylin and eosin staining
Mouse tumor tissues were fixed with formalin, embed-
ded with paraffin, spliced into 6-μm sections, deparaffi-
nized with xylene, and submerged into EDTA antigenic
retrieval buffer for antigenic retrieval. Lung sections
were stained with hematoxylin-eosin. Digital images of
organs were acquired by Nanozoomer (Hamamatsu
Photonics).
Immunohistochemical staining
For immunohistochemical staining, tissues sections were
incubated at 4 °C overnight with FOXD3 antibody
(ab67758, 1:200, Abcam, Cambridge, MA, USA) or
phosphorylated STAT3 (Tyr705) antibody (sc-8059,
1:200, Santa Cruz, Dallas, TX, USA). Sections were then
rinsed in PBS-T (PBS containing 0.05 % Triton X-100),
and secondary antibody was then added at a 1:500 dilu-
tion at room temperature for 1 h. After washing twice
with PBS-T, the slides were incubated with streptavidin-
horseradish peroxidase and diaminobenzidine substrate
for colorimetric development.
Statistical analyses
All data were expressed as mean ± standard deviation.
Two variables of microarray data and qRT-PCR data
were analyzed using Student’s t-test. The 5-year survival
rate analyses of cancer patients were performed using
log-rank (Mantel–Cox) test. A P value of <0.05 was con-
sidered significant.
Ethics
The Ethics Committee of Shanghai Jiao Tong University
approved our study. All participants provided written
informed consent prior to enrollment. All experimental
methods complied with the Helsinki Declaration. All
animal studies have been approved by the Shanghai
Jiao Tong University Institute Animal Care and Use
Committee, and all mice were kept in the Shanghai
Jiao Tong University School of medicine animal facilities.
Data availability
Our Agilent Human LncRNA microarray data have been
approved and assigned GEO accession numbers as
GSE76583. You may view the GSE76583 study at: http://
130.14.29.110/geo/query/acc.cgi?acc=GSE76583.
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